Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study

Fig. 2

Impact of Combi Treatment Relative to Mono Treatment on Outcome Events. Hazard ratios for each outcome event in the Combi group relative to the Mono group according to the univariable and multivariable mixed-effects Cox proportional hazards model using all treatment lines (Mono 96, Combi 51). The multivariate results include hazard ratios calculated from the model with the lowest Bayesian Information Criterion (BIC) and no missing values, with treatment failure as the dependent variable. Additionally, pooled hazard ratios are shown by combining results from all models. Abbreviations: CI, confidence interval; DAS28, Disease Activity Score in 28 Joints; HAQ-DI, Health Assessment Questionnaire-Disability Index; JAKi, Janus kinase inhibitors; TNF, tumor necrosis factor

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us